| pubmed-article:19596646 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C0005532 | lld:lifeskim |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:19596646 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:19596646 | pubmed:dateCreated | 2009-7-14 | lld:pubmed |
| pubmed-article:19596646 | pubmed:abstractText | Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is estimated that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone receptor/HER2-negative) phenotype. Most, though not all, triple-negative breast cancers will be basal-like on gene expression micorarrays. The basal-like molecular subtype exhibits a unique molecular profile and set of risk factors, aggressive and early pattern of metastasis, limited treatment options, and poor prognosis. Large population-based studies have identified a higher proportion of triple-negative breast tumors among premenopausal African American women, and a suggestion that increased parity, younger age at first-term pregnancy, shorter duration of breast feeding, and elevated hip-to-waist ratio might be particular risk factors. When BRCA1 mutation carriers develop breast cancer, it is usually basal-like; given the central role of BRCA1 in DNA repair, this could have profound therapeutic implications. When diagnosed, triple-negative breast cancers illustrate preferential relapse in visceral organs, including the central nervous system. Although initial response to chemotherapy might be more profound, relapse is early and common among triple-negative breast cancers compared with luminal breast cancers. The armamentarium of "targeted therapeutics" for triple-negative breast cancer is evolving and includes strategies to inhibit angiogenesis, epidermal growth factor receptor, and other kinases. Finally, the positive association between triple-negative breast cancer and BRCA mutations makes inhibition of poly(adenosine diphosphate-ribose) polymerase-1 an attractive therapeutic strategy that is in active study. | lld:pubmed |
| pubmed-article:19596646 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19596646 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19596646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19596646 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19596646 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19596646 | pubmed:issn | 1938-0666 | lld:pubmed |
| pubmed-article:19596646 | pubmed:author | pubmed-author:CareyLisa ALA | lld:pubmed |
| pubmed-article:19596646 | pubmed:author | pubmed-author:AndersCarey... | lld:pubmed |
| pubmed-article:19596646 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19596646 | pubmed:volume | 9 Suppl 2 | lld:pubmed |
| pubmed-article:19596646 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19596646 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19596646 | pubmed:pagination | S73-81 | lld:pubmed |
| pubmed-article:19596646 | pubmed:dateRevised | 2011-5-5 | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:meshHeading | pubmed-meshheading:19596646... | lld:pubmed |
| pubmed-article:19596646 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19596646 | pubmed:articleTitle | Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. | lld:pubmed |
| pubmed-article:19596646 | pubmed:affiliation | Department of Medicine, Division of Hematology-Oncology, University of North Carolina at Chapel Hill, 27599, USA. | lld:pubmed |
| pubmed-article:19596646 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19596646 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19596646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19596646 | lld:pubmed |
